Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WITH-HF-2 dual maintenance versus continued multidrug therapy in heart failure with improved ejection fraction
KCT0012756Phase 4Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of carvedilol and canrenoic acid in heart failure (HF) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Primary composite endpoint, Cardiovascular death and 4 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
carvedilolcanrenoic acid
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on KCT0012756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012756.